References
1. Saddi V, Beggs S, Bennetts B, et al. Childhood interstitial lung
diseases in immunocompetent children in Australia and New Zealand: a
decade’s experience. Orphanet J Rare Dis. 2017;12(1):133.
2. Griese M, Seidl E, Hengst M, et al. International management platform
for children’s interstitial lung disease (chILD-EU). Thorax.2018;73(3):231-239.
3. Torrent-Vernetta A, Gaboli M, Castillo-Corullon S, et al. Incidence
and Prevalence of Children’s Diffuse Lung Disease in Spain. Arch
Bronconeumol. 2022;58(1):22-29.
4. Deutsch GH, Young LR, Deterding RR, et al. Diffuse lung disease in
young children: application of a novel classification scheme. Am J
Respir Crit Care Med. 2007;176(11):1120-1128.
5. Fan LL, Dishop MK, Galambos C, et al. Diffuse Lung Disease in
Biopsied Children 2 to 18 Years of Age. Application of the chILD
Classification Scheme. Ann Am Thorac Soc. 2015;12(10):1498-1505.
6. Griese M. Etiologic Classification of Diffuse Parenchymal
(Interstitial) Lung Diseases. J Clin Med. 2022;11(6).
7. Nathan N, Griese M, Michel K, et al. Diagnostic workup of childhood
interstitial lung disease. Eur Respir Rev. 2023;32(167).
8. Cunningham S, Jaffe A, Young LR. Children’s interstitial and diffuse
lung disease. Lancet Child Adolesc Health. 2019;3(8):568-577.
9. Seidl E, Schwerk N, Carlens J, et al. Healthcare resource utilisation
and medical costs for children with interstitial lung diseases (chILD)
in Europe. Thorax. 2022;77(8):781-789.
10. Seidl E, Schwerk N, Carlens J, et al. Acute exacerbations in
children’s interstitial lung disease. Thorax. 2022;77(8):799-804.
11. Casey AM, Deterding RR, Young LR, Fishman MP, Fiorino EK, Liptzin
DR. Overview of the ChILD Research Network: A roadmap for progress and
success in defining rare diseases. Pediatr Pulmonol.2020;55(7):1819-1827.
12. Casamento K, Laverty A, Wilsher M, et al. Assessing the feasibility
of a web-based registry for multiple orphan lung diseases: the
Australasian Registry Network for Orphan Lung Disease (ARNOLD)
experience. Orphanet J Rare Dis. 2016;11:42.
13. Cunningham S, Gilbert C, Schwerk N, Ch ICRCMC, Members of the Ch
ICRCMC. The European research collaboration for Children’s Interstitial
Lung Disease (ChILDEU) ERS Clinical Research Collaboration. Eur
Respir J. 2018;52(6).
14. Young LR, Trapnell BC, Mandl KD, Swarr DT, Wambach JA, Blaisdell CJ.
Accelerating Scientific Advancement for Pediatric Rare Lung Disease
Research. Report from a National Institutes of Health-NHLBI Workshop,
September 3 and 4, 2015. Ann Am Thorac Soc. 2016;13(12):385-393.
15. Young LR, Nevel RJ, Casey AMH, et al. The National Registry for
Childhood Interstitial and Diffuse Lung Diseases: An Initial Report from
the ChILD Research Network. B97. IMPORTANCE OF LONGITUDINAL COHORT
STUDIES IN PEDIATRICS. Am J Respir Crit Care Med. A4191-A4191.
16. PA Harris RT, R Thielke, J Payne, N Gonzalez, JG Conde. Research
electronic data capture (REDCap) – A metadata-driven methodology and
workflow process for providing translational research informatics
support. J Biomed Inform. 2009;42(2):377-381.
17. PA Harris RT, BL Minor, V Elliott, M Fernandez, L O’Neal, L McLeod,
G Delacqua, F Delacqua, J Kirby, SN Duda, REDCap Consortium. The REDCap
consortium: Building an international community of software partners.J Biomed Inform. 2019;95:103208.
18. Fan LL, Kozinetz CA. Factors influencing survival in children with
chronic interstitial lung disease. Am J Respir Crit Care Med.1997;156(3 Pt 1):939-942.
19. Bureau USC. QuickFacts: Race and Hispanic Origin. 2020.
20. Griese M, Kappler M, Stehling F, et al. Randomized controlled phase
2 trial of hydroxychloroquine in childhood interstitial lung disease.Orphanet J Rare Dis. 2022;17(1):289.
21. Deterding R, Young LR, DeBoer EM, et al. Nintedanib in children and
adolescents with fibrosing interstitial lung diseases. European
Respiratory Journal. 2022:2201512.